Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 12/20 | 0.33 |
| ▸ | MMP2 | P08253 | 11/20 | 0.33 |
| ▸ | MMP1 | P03956 | 10/20 | 0.33 |
| ▸ | MMP7 | P09237 | 4/20 | 0.33 |
| ▸ | Q9HBH1 | 3/20 | 0.33 | |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 3/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401380 | 0.82 | SMN1; SMN2 (0.36) | MMP3MMP2MMP1MMP7PDF | |
| SCHEMBL12401210 | 0.82 | SMN1; SMN2 (0.36) | MMP3MMP2MMP1MMP7PDF | |
| SCHEMBL12401204 | 0.80 | MMP1 (0.39) | CYP2C9MMP3MMP2MMP1MMP7 | |
| SCHEMBL12401154 | 0.79 | PHF8 (0.39) | MMP13KDM4ELMNA | |
| SCHEMBL12401071 | 0.79 | ALDH1A1 (0.37) | MMP13ALDH1A1LMNA | |
| SCHEMBL23052280 | 0.78 | CYP2C9 (0.41) | CYP2C9MMP3MMP2MMP1MMP7 | |
| SCHEMBL18462936 | 0.78 | CYP2C9 (0.41) | CYP2C9MEN1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL10067158 | 0.78 | CYP2C9 (0.41) | CYP2C9MEN1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL18462935 | 0.77 | CYP2C9 (0.43) | CYP2C9MEN1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL17664757 | 0.76 | CYP2C9 (0.39) | CYP2C9MMP3MMP2MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | CYP2C9 1014/4885MMP3 84/4885MMP2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.